Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies

Journal of Rheumatology

Volumn 37, Issue 11, 2010, Pages 2290-2298

  Avouac, Jérôme ^a   Airò, Paolo ^b   Meune, Christophe ^a   Beretta, Lorenzo ^c   Dieude, Philippe ^a   Caramaschi, Paola ^d   Tiev, Kiet ^e   Cappelli, Susanna ^f   Diot, Elisabeth ^g   Vacca, Alessandra ^h   Cracowski, Jean Luc ⁱ   Sibilia, Jean ^j   Kahan, André ^a   Matucci Cerinic, Marco ^f   Allanore, Yannick ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Rheumatology and Immunology Unit   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e HÔPITAL SAINT ANTOINE   (France)

^f Section of Rheumatology   (Italy)

^g CHU BRETONNEAU   (France)

^h UNIVERSITY OF CAGLIARI   (Italy)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j UNIVERSITÉ DE STRASBOURG   (France)

more..

Author keywords

Catheterization; Metaanalysis; Prevalence; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

AGE; AGED; ARTICLE; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DOPPLER ECHOGRAPHY; EUROPE; FRANCE; HEART CATHETERIZATION; HIGH RISK PATIENT; HUMAN; INTERSTITIAL LUNG DISEASE; ITALY; LUNG ALVEOLUS; LUNG FUNCTION TEST; META ANALYSIS; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; SYSTEMIC SCLEROSIS;

AGE FACTORS; AGED; COMORBIDITY; ECHOCARDIOGRAPHY, DOPPLER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 78149259521     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100245     Document Type: Article

References (42)

1. Proceedings of the 4th World Symposium on Pulmonary Hypertension, February 2008, Dana Point, California, USA. J Am Coll Cardiol 2009;54:S1-117.
2. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S-62S.
3. Allanore Y, Avouac J, Wipff J, Kahan A. New therapeutic strategies in the management of systemic sclerosis. Expert Opin Pharmacother 2007;8:607-15. (Pubitemid 46547014)
4. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006;54:3043-50.
5. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
6. Avouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2008;67:808-14. (Pubitemid 351829381)
7. Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008;35:458-65.
8. Pope JE, Lee P, Baron M, Dunne J, Smith D, Docherty PS, et al. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005;32:1273-8.
9. Dorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G, Muller KM, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007;38:893-902. (Pubitemid 46735956)
10. Mukerjee D, St. George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
11. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
12. Hachulla E. [Treatment of pulmonary arterial hypertension associated to systemic sclerosis]. Rev Med Interne 2004;25:195-200.
13. Cox SR, Walker JG, Coleman M, Rischmueller M, Proudman S, Smith MD, et al. Isolated pulmonary hypertension in scleroderma. Intern Med J 2005;35:28-33.
14. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22.
15. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-7.
16. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
17. Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L, et al. Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis Rheum 2008;58:1803-9.
18. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008;58:284-91.
19. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40.
20. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton C, et al. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension. Results of a systematic literature analysis by the EPOSS group. J Rheumatol 2009;37:105-15.
21. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000;162:1964-73.
22. Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of systemic sclerosis patients. Ann Rheum Dis 2010;69:218-21.
23. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
24. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
25. Freeman M, Turkey J. Transformations related to the angular and the square root. Ann Math Statistics 1950;21:607-11.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
27. Trinquart L, Touze E. Pitfalls in meta-analysis of observational studies: lessons from a systematic review of the risks of stenting for intracranial atherosclerosis. Stroke 2009;40:e586-587; author reply: e590.
28. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
29. Egger M, Smith GD. Bias in location and selection of studies. BMJ 1998;316:61-6.
30. Vonk MC, Broers B, Heijdra YF, Ton E, Snijder R, van Dijk AP, et al. Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study. Ann Rheum Dis 2009;68:961-5.
31. Phung S, Strange G, Chung LP, Leong J, Dalton B, Roddy J, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009;39:682-91.
32. Mukerjee D, St. George D, Knight C, Davar J, Wells AU, Du Bois RM, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004;43:461-6.
33. Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52:2125-32.
34. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:14S-34S.
35. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S-47S.
36. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23.
37. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361:1533-44.
38. Hachulla E, Launay D, Mouthon L, Sitbon O, Berezne A, Guillevin L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 2009;136:1211-9.
39. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007;37:485-94.
40. Gabbay E, Reed A, Williams TJ. Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006. Intern Med J 2007;37:38-48.
41. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42.
42. Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 2005;32:1488-94.